Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study
Abstract Background Mucopolysaccharidosis (MPS) IVA, also known as Morquio A syndrome, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase. Early recognition, diagnosis, and treatment of this progressive, multisystem disease...
Main Authors: | Can Ficicioglu, Dena R. Matalon, Nicole Luongo, Caitlin Menello, Tracy Kornafel, Andrew J. Degnan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-11-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13023-020-01618-y |
Similar Items
-
Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
by: Hsiang-Yu Lin, et al.
Published: (2018-08-01) -
Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes
by: Juan Politei, et al.
Published: (2021-03-01) -
Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks
by: Andrés Felipe Leal, et al.
Published: (2023-11-01) -
Mucopolysaccharidosis type IVA in children: Clinical cases
by: A. V. Burlutskaya, et al.
Published: (2022-02-01) -
Role of elosulfase alfa in mucopolysaccharidosis IVA
by: Regier DS, et al.
Published: (2016-06-01)